Who Paid My Doc
Patrick Brillant
Colon & Rectal Surgery Greenville, NC Medical Doctor
NPI 1275538639 CMS profile 148203
1850 W Arlington Blvd, Greenville, NC 27834
General payments
$710
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Patrick Brillant of Greenville, NC is reported in the CMS Open Payments database as having received $710 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 26th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $47 | 1 | |
| 2024 | General | $138 | 1 | |
| 2023 | General | $19 | 1 | |
| 2022 | General | $18 | 1 | |
| 2021 | General | $78 | 1 | |
| 2019 | General | $411 | 9 |
Beside peers
- Patrick Brillant
- Colon & Rectal Surgery median
- Middle half of Colon & Rectal Surgery
- National median
In program year 2025, general payments to Patrick Brillant were reported at $47. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.
Show as a table
| Year | Patrick Brillant | Colon & Rectal Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $411 | $443 | $125–$2,179 | $163 |
| 2020 | $0 | $167 | $53–$931 | $114 |
| 2021 | $78 | $207 | $72–$1,272 | $132 |
| 2022 | $18 | $341 | $111–$1,587 | $149 |
| 2023 | $19 | $322 | $115–$1,420 | $160 |
| 2024 | $138 | $328 | $112–$1,354 | $164 |
| 2025 | $47 | $317 | $109–$1,248 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
326
Drug cost
$5,843
Branded share of claims
71.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | Brand | 116 | $2,101 | |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | Brand | 27 | $1,827 | |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | Brand | 52 | $861 | |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | Brand | 18 | $441 | |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | Brand | 21 | $356 | |
| Neomycin Sulfate | Generic | 43 | $153 | |
| Metronidazole | Generic | 49 | $105 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 134 billing codesPaid by Medicare
$132,376
Medicare patients
408
Services billed
7,311
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 43% | |
| Diabetes | 36% | |
| Ischemic heart disease | 32% | |
| Cancer | 32% | |
| Chronic kidney disease | 24% | |
| Depression | 21% | |
| Osteoporosis | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 30 | 3,250 | $310 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Colon & Rectal Surgery in North Carolina
Benny Chong
Colon & Rectal Surgery · Concord, NC
Coen Klos
Colon & Rectal Surgery · Hendersonville, NC
Julie Thacker
Colon & Rectal Surgery · Durham, NC
William Lyman
Colon & Rectal Surgery · Charlotte, NC
Joseph Payne
Colon & Rectal Surgery · Wilmington, NC
Stanley Fuller
Colon & Rectal Surgery · Winston Salem, NC
Related records
Colon & Rectal Surgery in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Colon & Rectal Surgery
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.